| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
MLS1547 targets the dopamine D2 receptor (D2R), a G protein-coupled receptor involved in motor control, reward, and neuropsychiatric disorders. It is a G protein-biased agonist, meaning it preferentially activates G protein signaling pathways over β-arrestin recruitment.
|
|---|---|
| ln Vitro |
MLS1547 completely inhibited dopamine-mediated beta-arrestin recruitment to D2R in the DiscoveRx assay, with an IC50 of 9.9 μM. Analogous outcomes were seen when analyzing MLS1547's antagonist activity using the D2R β-arrestin BRET assay, revealing an IC50 of 3.8 μM. [3H]methylspiroperone bound to the D2R was found to be entirely replaced by MLS1547, with an estimated Ki of 1.2 μM [1].
In vitro, MLS1547 stimulates D2R G protein-mediated signaling in calcium mobilization assays with an EC50 of 0.37 µM. It inhibits forskolin-induced cAMP accumulation in CHO cells expressing human D2 receptors with an EC50 of 0.26 µM. It is inactive in β-arrestin recruitment assays, confirming its G protein bias. |
| ln Vivo |
In vivo studies for MLS1547 are limited. As a research tool, it is used to study dopamine signaling and the development of antipsychotics with reduced side effects. Detailed in vivo efficacy data have not been published.
|
| Enzyme Assay |
The in vitro receptor binding assay for MLS1547 involves measuring its affinity for the dopamine D2 receptor using radioligand binding techniques. Membrane preparations from cells expressing D2R are incubated with a radiolabeled antagonist and varying concentrations of MLS1547. The Ki is determined by competition binding analysis.
|
| Cell Assay |
Cellular assays for MLS1547 involve measuring G protein-mediated signaling in cells expressing the dopamine D2 receptor. Calcium mobilization is measured using a fluorescent calcium indicator, and the EC50 for stimulation is determined. The inhibition of forskolin-induced cAMP accumulation is measured using a cAMP assay kit. β-arrestin recruitment is assessed using a BRET or enzyme fragment complementation assay.
|
| Animal Protocol |
In vivo animal studies for MLS1547 are not well-documented. As a research compound, it may be evaluated in animal models of dopamine-related behaviors, but specific protocols have not been published.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MLS1547 have not been extensively characterized. It has a molecular weight of 354.83 g/mol and a molecular formula of C19H19ClN4O.
|
| Toxicity/Toxicokinetics |
Limited toxicity data are available for MLS1547. It is a research-grade compound, and comprehensive toxicological evaluations have not been published.
|
| References |
[1]. Free RB, et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol. 2014;86(1):96-105.
[2]. Chun LS, et al. Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Front Synaptic Neurosci. 2018;10:2. Published 2018 Feb 21. |
| Additional Infomation |
MLS1547 is a research compound for studying dopamine D2 receptor signaling and biased agonism. It has not entered clinical trials. Its mechanism involves G protein-biased partial agonism at D2R, making it a valuable tool for investigating the therapeutic potential of biased ligands for neuropsychiatric disorders.
|
| Molecular Formula |
C19H19CLN4O
|
|---|---|
| Molecular Weight |
354.838
|
| Exact Mass |
354.124
|
| Elemental Analysis |
C, 64.31; H, 5.40; Cl, 9.99; N, 15.79; O, 4.51
|
| CAS # |
315698-36-3
|
| PubChem CID |
1093278
|
| Appearance |
Solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
555.8±50.0 °C at 760 mmHg
|
| Flash Point |
289.9±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.689
|
| LogP |
3.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(N2CCN(CC3C=C(Cl)C4=CC=CN=C4C=3O)CC2)N=C1
|
| InChi Key |
OPEJNANYABTIGC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H19ClN4O/c20-16-12-14(19(25)18-15(16)4-3-7-22-18)13-23-8-10-24(11-9-23)17-5-1-2-6-21-17/h1-7,12,25H,8-11,13H2
|
| Chemical Name |
5-chloro-7-[(4-pyridin-2-ylpiperazin-1-yl)methyl]quinolin-8-ol
|
| Synonyms |
MLS 1547; MLS-1547; MLS1547
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~93.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8182 mL | 14.0909 mL | 28.1817 mL | |
| 5 mM | 0.5636 mL | 2.8182 mL | 5.6363 mL | |
| 10 mM | 0.2818 mL | 1.4091 mL | 2.8182 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
